Yeou-Ping Tsao

This inventor holds 16 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 9 EPO patents. Top assignees: Mackay Memorial Hospital, Brim Biotechnology, Inc., Mackay Memorial Hosptal. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yeou-Ping Tsao. Retrieved from https://idiyas.com/inventor/yeou-ping-tsao

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 3)

% Patents Active = 93.8

CIPO Patents = 2

EPO Patents = 9 (Patent Applications = 16)

Average Co-Inventor Count = 2.2

ph-index = 1

Forward Citations = 2(Granted Patents)

Company Filing History:

14 out of 53

Mackay Memorial Hospital

patents

1 out of 1

Brim Biotechnology, Inc.

patent

1 out of 1

Mackay Memorial Hosptal

patent

Years Active: 2013-2026

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12559725 - FORMULATION COMPRISING EXTRACELLULAR VESICLES, METHOD FOR PRODUCING THE SAME, AND USES THEREOF (2026-02-24),

2. 12221494 - Short synthetic peptides and their uses for treating retinal degenerative diseases and/or tissue injuries (2025-02-11),

3. 11760784 - Compositions comprising PEDF-derived short peptides and uses thereof (2023-09-19),

4. 11692172 - Formulation comprising extracellular vesicles, method for producing the same, and uses thereof (2023-07-04),

5. 10875891 - Short synthetic peptide and uses thereof (2020-12-29),

6. 10562932 - Short synthetic peptide and uses thereof (2020-02-18),

7. 10463710 - Short synthetic peptide for the treatment and/or prophylaxis of autoimmune and inflammatory disorders (2019-11-05),

8. 10463709 - Short synthetic peptide for treating diseases and/or conditions related to angiogenesis (2019-11-05),

9. 10307456 - Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease (2019-06-04),

10. 9938328 - Use of PEDF-derived polypeptides for treating alopecia and/or hair depigmentation (2018-04-10),

11. 9884012 - Use of PEDF-derived polypeptides for promoting muscle or tendon regeneration or arteriogenesis (2018-02-06),

12. 9815878 - Use of PEDF-derived polypeptides for preventing and/or ameliorating skin aging (2017-11-14),

13. 9777048 - Use of PEDF-derived polypeptides for treating osteoarthritis (2017-10-03),

14. 9617311 - Use of PEDF-derived polypeptides for promoting stem cells proliferation and wound healing (2017-04-11),

15. 9051547 - Use of PEDF-derived polypeptides for promoting stem cells proliferation and wound healing (2015-06-09),

Title: Yeou-Ping Tsao: Innovator in Retinal Treatment

Introduction

Yeou-Ping Tsao is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of medical science, particularly in the treatment of retinal degenerative diseases. With a total of 16 patents to his name, Tsao's work has the potential to impact many lives.

Latest Patents

Among his latest patents is a formulation comprising extracellular vesicles, which outlines a method for producing these vesicles and their various uses. Another notable patent involves short synthetic peptides designed for treating retinal degenerative diseases and tissue injuries. This patent discloses synthetic peptides and compositions that can be administered to subjects in need of treatment for retinal conditions.

Career Highlights

Yeou-Ping Tsao has worked at Mackay Memorial Hospital, where he has been involved in groundbreaking research and development. His work at this institution has allowed him to explore innovative solutions for complex medical issues.

Collaborations

Throughout his career, Tsao has collaborated with notable colleagues, including Tsung-Chuan Ho and Kuanyin Karen Lin. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Yeou-Ping Tsao's contributions to the field of retinal treatment through his innovative patents and collaborations highlight his dedication to advancing medical science. His work continues to pave the way for new therapeutic approaches in treating retinal degenerative diseases.

Profile summary based on public USPTO records.